September 8, 2020 News by Joana Carvalho, PhD Bafiertam, Oral Relapsing MS Therapy, Arrives in US Bafiertam (monomethyl fumarate), a bioequivalent of TecfideraĀ to treat relapsing forms of multiple sclerosis (MS), is now available to patients in the U.S. through a network of specialty pharmacies, Banner Life Sciences, the therapyās developer, announced. Banner previously stated that Bafiertam would arrive on the market…
July 20, 2020 News by Forest Ray PhD Bafiertam, for Adults With Relapsing MS, Available in US in September Banner Life Sciences announced thatĀ Bafiertam (monomethyl fumarate) will become available to adults with relapsing forms of multiple sclerosis (MS) in the United States beginning in September. The U.S. Food and Drug AdministrationĀ (FDA)Ā approved Bafiertam in April as a bioequivalent to BiogenāsĀ Tecfidera…
June 5, 2020 Columns by Ed Tobias Another Medication, Zeposia, Joins the MS Treatment Arsenal By my unofficial count, disease-modifying therapy No. 19 has just become available to people with multiple sclerosis in the U.S. The U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) in late March. While pharmaceutical companies usually rush to make newly approved medications available to patients, with COVID-19 raging,…
July 25, 2019 News by Steve Bryson, PhD Tecfidera Up Against Bafiertam in Phase 1 Study of GI Tolerability A first healthy volunteer has enrolled in a randomized, double-blind Phase 1 study to compare the gastrointestinal (GI) tolerability and safety of oral Tecfidera to Bafiertam, an oralĀ bioequivalent in treating relapsing forms of multiple sclerosis (MS),Ā Banner Life Sciences…
January 7, 2019 Columns by Ed Tobias MS News that Caught My Eye Last Week: Stem Cell Transplant, Cooling Therapy and Exercise, FDA OK for Generic Tecfidera, Top Stories of 2018 Stem Cell Transplant Lessens Disability and Relapses in RRMS Patients, Phase 2 Trial Shows Here’s another study indicating that a stem cell transplant should be a treatment choice available to all MS patients where medically appropriate. Isn’t it past time to press harder on the stem cell…
January 4, 2019 News by Alberto Molano, PhD Bafiertam, a Bioequivalent of Tecfidera, Receives Tentative OK from FDA for RRMS Banner Life SciencesĀ has received tentative approval from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) for Bafiertam (monomethyl fumarate), a novel bioequivalent of Biogenās Tecfidera (dimethyl fumarate) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Final approval is expected no later than…